atorvastatin has been researched along with methotrexate in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (31.25) | 29.6817 |
| 2010's | 10 (62.50) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Capell, HA; Ford, I; Hampson, R; Madhok, R; McCarey, DW; McInnes, IB; Sattar, N; Scherbakov, O | 1 |
| Fabian, V; Knezevic, W; Mastaglia, FL; Needham, M; Panegyres, P; Zilko, P | 1 |
| El-Barbary, AM; Hamouda, HE; Hussein, MS; Ismail, RG; Rageh, EM; Wagih, AA | 1 |
| Flores, RM; Kanth, R; Shah, MS | 1 |
| Abdel-Rahman, MN; El Rashidy, MA; El-Sisi, Ael-D; Ezzat, NM; Haleem, MS; Kabel, AM | 1 |
| Akhtar, S; Desai, A; Goldwater, R; Han, D; Howieson, C; Kowalski, D; Lademacher, C; Lasseter, KC; Rammelsberg, D; Townsend, R; Yamazaki, T | 1 |
| Ahn, KW; Atallah, E; Boyd, J; Bunner, P; Carlson, KS; Craig, M; Cumpston, A; D'Souza, A; Drobyski, W; Fenske, TS; Guru Murthy, GS; Hamadani, M; Hari, PN; Horowitz, MM; Kanate, AS; Michaelis, L; Pasquini, MC; Rizzo, JD; Saber, W; Visotcky, A | 1 |
| Du, W; Han, B; Hou, J; Hou, S; Huang, X; Liu, D; Liu, Q; Lv, H; Nie, H; Sun, Y; Wang, G; Wang, X; Yang, M; Yu, B; Zhang, L; Zhang, R | 1 |
| El-Sayyad, SM; Ibrahim, SSA; Kandil, LS; Ragab, GM | 1 |
1 review(s) available for atorvastatin and methotrexate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 trial(s) available for atorvastatin and methotrexate
| Article | Year |
|---|---|
Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Atorvastatin; Biomarkers; Blood Sedimentation; Blood Viscosity; C-Reactive Protein; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Glucocorticoids; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Methotrexate; Middle Aged; Pyrroles; Risk Factors; von Willebrand Factor | 2004 |
Effect of atorvastatin on inflammation and modification of vascular risk factors in rheumatoid arthritis.
Topics: Adiponectin; Adult; Aged; Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Atorvastatin; Drug Therapy, Combination; Endothelium, Vascular; Female; Forearm; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Methotrexate; Middle Aged; Prednisone; Pyrroles; Regional Blood Flow; Resistin; Risk Factors; Severity of Illness Index; Tumor Necrosis Factor-alpha | 2011 |
Pharmacokinetic Interactions Between Isavuconazole and the Drug Transporter Substrates Atorvastatin, Digoxin, Metformin, and Methotrexate in Healthy Subjects.
Topics: Adult; Area Under Curve; Atorvastatin; Digoxin; Female; Healthy Volunteers; Humans; Male; Membrane Transport Proteins; Metformin; Methotrexate; Middle Aged; Nitriles; Pyridines; Triazoles; Young Adult | 2017 |
Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation.
Topics: Adult; Aged; Allografts; Atorvastatin; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Male; Methotrexate; Middle Aged; Prospective Studies; Survival Rate; Tacrolimus | 2017 |
11 other study(ies) available for atorvastatin and methotrexate
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Rheumatoid arthritis treatment progressing.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Arthritis, Rheumatoid; Atorvastatin; Cyclophosphamide; Drug Therapy, Combination; Heptanoic Acids; Humans; Methotrexate; Pyrroles; Rituximab | 2004 |
Progressive myopathy with up-regulation of MHC-I associated with statin therapy.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Atorvastatin; Creatine Kinase; Female; Folic Acid Antagonists; Genes, MHC Class I; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Male; Methotrexate; Middle Aged; Mitochondria, Muscle; Muscle Weakness; Muscular Diseases; Prednisolone; Pyrroles; Sarcolemma; Simvastatin; Up-Regulation | 2007 |
Statin-associated polymyositis following omeprazole treatment.
Topics: Anticholesteremic Agents; Atorvastatin; Drug Interactions; Esophagitis; Gemfibrozil; Heptanoic Acids; Humans; Male; Methotrexate; Middle Aged; Myocardial Infarction; Omeprazole; Polymyositis; Prednisone; Proton Pump Inhibitors; Pyrroles; Treatment Outcome; Withholding Treatment | 2013 |
Effect of atorvastatin and methotrexate on solid Ehrlich tumor.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Atorvastatin; Carcinoma, Ehrlich Tumor; Catalase; Cholesterol; Glutathione Reductase; Heptanoic Acids; Immunohistochemistry; Male; Methotrexate; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Pyrroles; Tumor Necrosis Factor-alpha | 2013 |
Atheroprotective effects of methotrexate via the inhibition of YAP/TAZ under disturbed flow.
Topics: Adaptor Proteins, Signal Transducing; Adenylate Kinase; Animals; Apoptosis; Atherosclerosis; Atorvastatin; Cell Nucleus; Gene Silencing; Hemorheology; Human Umbilical Vein Endothelial Cells; Humans; Male; Methotrexate; Mice, Inbred C57BL; Models, Biological; Phosphorylation; Plaque, Atherosclerotic; Trans-Activators; Transcription Factors; Transcriptional Coactivator with PDZ-Binding Motif Proteins; YAP-Signaling Proteins | 2019 |
Micro RNAs 26b, 20a inversely correlate with GSK-3 β/NF-κB/NLRP-3 pathway to highlight the additive promising effects of atorvastatin and quercetin in experimental induced arthritis.
Topics: Alanine Transaminase; Animals; Antirheumatic Agents; Arthritis, Experimental; Aspartate Aminotransferases; Atorvastatin; CARD Signaling Adaptor Proteins; Carrier Proteins; Caspase 1; Cell Cycle Proteins; Correlation of Data; Cytokines; Glycogen Synthase Kinase 3 beta; I-kappa B Proteins; Male; Malondialdehyde; Methotrexate; MicroRNAs; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein; Quercetin; Rats, Sprague-Dawley; Signal Transduction | 2021 |